Intracutaneous reactivity testing is a critical biological safety evaluation that determines whether medical device materials or their extracts cause localized irritation when in contact with living tissue. Performed in accordance with ISO 10993-10 and the equivalent Chinese national standard GB/T 16886.10, this test is a mandatory component of biocompatibility assessment for devices that contact breached skin, mucous membranes, tissue, bone, or dentin. This article provides a comprehensive technical overview of the testing principles, sample requirements, methodology, scoring criteria, and regulatory applications of intracutaneous reactivity testing for medical devices.
Technical Overview
Intracutaneous reactivity testing, also referred to as the intradermal irritation test or intracutaneous injection test, is an in vivo biological evaluation designed to assess the potential of medical device extracts to produce localized irritation following direct injection into the skin. The test is specified in ISO 10993-10, which addresses tests for irritation and skin sensitization as part of the ISO 10993 series on the biological evaluation of medical devices, and in the corresponding Chinese national standard GB/T 16886.10. Because the intradermal route bypasses the protective outer layer of the skin, this method is deliberately more sensitive than topical patch testing and can detect irritant potential that surface-contact tests may fail to reveal.
Within the risk management framework defined by ISO 10993-1, intracutaneous reactivity data is generally expected for devices categorized as surface devices contacting breached or compromised surfaces, external communicating devices that contact tissue, bone, or dentin, and implantable devices. The test is typically conducted by accredited third-party laboratories under Good Laboratory Practice (GLP) conditions, with animal procedures reviewed and approved by an institutional animal care committee in accordance with the 3Rs principles of replacement, reduction, and refinement.
Testing Samples
Samples submitted for intracutaneous reactivity testing are prepared as extracts rather than tested directly, since the procedure requires injectable liquid preparations. The selection of extraction media and conditions follows ISO 10993-12, which governs sample preparation and reference materials.
Device Extracts
Two parallel extractions are prepared for each sample: a polar extraction using 0.9% sodium chloride injection solution (physiological saline) and a non-polar extraction using a pharmacopoeial-grade vegetable oil such as cottonseed oil or sesame oil. This dual-medium approach ensures that both hydrophilic and lipophilic leachable substances are captured for evaluation.
Representative Sample Types
- Catheters, infusion sets, syringes, and blood administration sets
- Wound dressings, hydrogels, and absorbable hemostatic materials
- Latex and synthetic gloves, condoms, and other barrier products
- Dental materials, bone cements, and restorative composites
- Polymer granules, cured sheets, and other raw material coupons
- Implant components, coatings, adhesives, and sterilization residues
- Primary packaging materials that directly contact the device
Sample Preparation Requirements
The standard extraction ratio is 0.2 g of test material per 1 mL of extraction medium for irregularly shaped solids, or 0.1 g per 1 mL where surface area calculation is more appropriate, with a ratio of 6 cm² per 1 mL applied to films, sheets, and tubular structures. Samples must be representative of the final product in its fully processed, sterilized, and packaged state, since manufacturing residues, molding aids, and sterilization by-products can significantly influence extract chemistry.
Testing Items
The core endpoints evaluated during intracutaneous reactivity testing are defined by the macroscopic grading system specified in ISO 10993-10:
- Erythema and eschar formation, graded from 0 (no reaction) to 4 (severe erythema with slight eschar formation)
- Edema, graded from 0 (no swelling) to 4 (severe swelling raised more than 1 mm and extending beyond the exposure zone)
- Combined intracutaneous irritation index, calculated as the sum of the erythema and edema scores
- Comparative assessment of test extract sites versus corresponding blank control sites
The blank controls consist of the extraction media alone, processed under identical conditions without the test material. These controls are essential for distinguishing genuine material-mediated irritation from reactions caused by the injection procedure itself or by the extraction medium.
Testing Methods
Extraction Procedure
Test materials are extracted under the standard condition of 37°C ± 1°C for 24 ± 2 hours in both polar and non-polar media. Where a more aggressive extraction is justified, ISO 10993-12 permits exaggerated conditions, including 50°C for 72 hours, 70°C for 24 hours, or 121°C for 1 hour. Following extraction, fluids are inspected, and any turbidity or particulate contamination is documented, as particles can cause mechanical trauma at the injection site and confound scoring.
Animal Model and Injection Protocol
The test is performed on healthy young adult albino rabbits weighing not less than 2 kg, with three animals typically used per test. Twenty-four hours before injection, the dorsal area is clipped free of fur. Each rabbit receives 0.2 mL intradermal injections at multiple sites along the back, including the polar test extract, the non-polar test extract, and the corresponding sham-extracted blank controls. The injection pattern is designed so that each test site is directly adjacent to its matching control, minimizing inter-animal and inter-site variability.
Observation and Scoring
Injection sites are examined at 24, 48, and 72 hours after administration. At each time point, a trained observer grades every site for erythema, eschar formation, and edema using the 0-to-4 numerical scale. Any additional observations, such as blistering, necrosis, or desquamation, are recorded descriptively even though they fall outside the numerical scale.
Acceptance Criteria and Interpretation
The result is interpreted by comparing the mean irritation score of the test extract sites with the mean score of the corresponding blank control sites. The test sample is considered to meet the requirements of ISO 10993-10 when the difference between the test and control mean scores does not exceed 1.0 for both the polar and non-polar extracts. A persistent difference greater than 1.0 indicates that the material produces significant intracutaneous irritation, and a root-cause investigation into leachables, processing aids, or sterilization residues is generally recommended before further product development or regulatory submission.
Applications
Intracutaneous reactivity testing serves multiple purposes across the medical device product lifecycle:
- Regulatory registration submissions, where biocompatibility documentation is required by authorities such as those evaluating compliance with the EU Medical Device Regulation, the United States FDA 510(k) and PMA pathways, and China's NMPA registration framework
- Biological safety screening of new materials, formulations, and supplier sources prior to design lock
- Change control evaluation following modifications to materials, manufacturing processes, molding parameters, adhesives, or sterilization methods
- Compliance demonstration for devices in ISO 10993-1 contact categories involving breached skin, mucosal membranes, tissue, bone, or dentin
- Substitution or supplementation of primary skin irritation testing for devices whose final use involves internal tissue contact or whose geometry makes topical application impractical
- Support of chemical characterization and toxicological risk assessment programs under ISO 10993-17
Because intracutaneous testing is more sensitive than surface irritation methods, a passing result frequently satisfies the irritation endpoint for several device categories simultaneously, streamlining the overall biocompatibility test battery and reducing total animal usage.
FAQ
What is intracutaneous reactivity testing?
It is an in vivo biological safety test in which polar and non-polar extracts of a medical device are injected intradermally into rabbits, and the resulting skin reactions are scored for erythema, eschar, and edema to determine whether the material has irritant potential.
Which standards govern the test?
The primary standard is ISO 10993-10, with sample preparation conducted per ISO 10993-12. In China, the equivalent national standard GB/T 16886.10 is accepted, and both frameworks are harmonized in their methodology and scoring criteria.
Why are two extraction media used?
Medical device materials may release both water-soluble and fat-soluble substances. Using saline as a polar medium and vegetable oil as a non-polar medium ensures that the full spectrum of extractable chemicals is evaluated for irritant potential.
How much sample is required for testing?
Sample quantity depends on the extraction ratio and the geometry of the device. As a general guideline, laboratories require sufficient material to achieve 0.2 g per mL of extraction medium for solid items, and clients are advised to confirm specific mass or surface-area requirements with the testing laboratory during project planning.
How long does the test take?
Excluding sample conditioning and report issuance, the core experimental phase, including extraction, animal acclimatization, injection, and the 72-hour observation period, is typically completed within two to four weeks in an accredited laboratory workflow.
Can intracutaneous reactivity testing replace a skin irritation test?
In many cases, yes. Because the intradermal route is more sensitive than topical application, a passing intracutaneous test is often accepted as evidence that the material will not irritate intact or breached skin, allowing the primary skin irritation study to be waived as part of a justified biological evaluation plan.
What should be done if a sample fails the test?
A result exceeding the acceptance threshold warrants an investigation into extractable substances, processing residues, degradation products, or sterilization by-products. Corrective actions may include material substitution, enhanced post-curing or cleaning procedures, or redesigned sterilization validation, followed by retesting to confirm improved biological performance.